[144] ANI Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

ANI Pharmaceuticals, Inc. (ANIP) submitted a Form 144 notifying the proposed sale of 9,000 shares of common stock via Morgan Stanley Smith Barney LLC on 08/15/2025. The filing lists an aggregate market value of $801,450.00 for those shares and reports 21,688,772 shares outstanding for the issuer. The 9,000 shares were acquired from the issuer as restricted stock on 03/23/2022, and no securities were reported sold by the seller in the past three months. The notice includes the required representation that the selling person is not aware of undisclosed material adverse information.

Positive

• Transparent disclosure of a proposed insider sale including broker, number of shares, acquisition date, and planned sale date
• Acquisition method disclosed: shares were acquired as restricted stock from the issuer on 03/23/2022
• No securities sold in past three months reported, indicating this is a new proposed sale rather than recent repeated sales

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider sale notice for 9,000 shares; provides transparency but contains no new financial results.

The filing is a standard Form 144 disclosure signaling a proposed sale by a person who acquired the shares as restricted stock on 03/23/2022. It specifies broker details, the planned sale date of 08/15/2025, aggregate market value of $801,450, and total shares outstanding of 21,688,772. There are no reported sales in the past three months, which indicates this is a newly announced sale rather than a continuation. This filing is informational and does not include operational or earnings data that would materially change valuation assumptions.

Corporate Governance Expert

TL;DR: Disclosure aligns with regulatory requirements; filing affirms seller's representation about material nonpublic information.

The Form 144 contains the required elements: issuer identification, broker, number of shares to be sold, acquisition details (restricted stock from the issuer on 03/23/2022), and the seller's certification regarding material adverse information. From a governance perspective, the filing documents an insider-originated sale process handled through a registered broker. The document does not disclose any trading plan adoption date or additional governance actions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	9000	801450.00	21688772	08/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/23/2022	Restricted Stock	Issuer			9000	03/23/2022	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does ANI Pharmaceuticals' Form 144 disclose about the planned sale?

It discloses a proposed sale of 9,000 common shares through Morgan Stanley Smith Barney LLC with an approximate aggregate market value of $801,450 and an approximate sale date of 08/15/2025.

How and when were the 9,000 shares acquired according to the filing?

The filing states the shares were acquired as restricted stock from the issuer on 03/23/2022.

Does the Form 144 report any sales of ANI Pharmaceuticals stock by the seller in the past three months?

The filing indicates Nothing to Report for securities sold during the past three months.

Which broker is named to execute the proposed sale in the Form 144?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza 8th Floor, New York, NY 10004.

What representation does the seller make in the Remarks section of the Form 144?

The seller represents by signing that they do not know any material adverse information about the issuer that has not been publicly disclosed.